The Regulator

HHS will not raise its civil monetary penalty amounts for 2026, leaving 2025 levels in place. The Department of Health and Human Services (HHS) published a notice in today’s Federal Register saying there is no cost-of-living adjustment this year, following guidance from the Office of Management and Budget (OMB) issued April 17, 2026. Who it hits: providers, plans and suppliers facing federal civil penalties, whose maximum per-violation amounts stay flat instead of ratcheting up. So what: penalty ceilings do not rise this year, though the notice does not change settlement practice or False Claims Act damages, which are set separately. I could not retrieve the full notice text, so the list of affected penalty categories is not confirmed here. Confidence: High on the no-adjustment decision; Low on category-level detail. Sources: Federal Register, HHS civil monetary penalty notice (2026-21524).

The Food and Drug Administration (FDA) approved GSK’s Hibsago on October 20, the first antisense drug for chronic hepatitis B. Hibsago (bepirovirsen) is a subcutaneous injection given for up to 24 weeks, on top of existing antiviral therapy, for certain adults without cirrhosis whose virus is already suppressed. In two placebo-controlled trials, 24% of Hibsago patients met criteria to stop their existing medicine, versus none on placebo, and 19% still had the virus controlled, with surface antigen undetectable, 24 weeks after stopping all treatment. It carries a boxed warning for serious liver reactions and low platelet counts. FDA gave no price and no U.S. patient count, so the budget impact for payers is not yet knowable. Confidence: High on approval and trial figures. Sources: FDA press announcement.

The FDA finalized guidance October 20 on when apps paired with prescription drugs count as drug labeling. Apps connected to a medical device, such as an inhaler, generally should be described in the drug’s prescribing information. Standalone apps, such as symptom trackers, dose reminders and health coaching tools, belong on the label only if the company shows the app is essential for safe and effective use or gives a meaningful clinical benefit; their content is usually treated as promotional material. Who it hits: drug makers and their software partners. So what: apps that fall on the promotional side face the same advertising rules as other drug marketing. The guidance was published in the Federal Register as document 2026-21516 today. Confidence: High. Sources: FDA press announcement, Federal Register notice (2026-21516).

The FDA approved the first generic of Bayer’s Climara Pro menopause patch. Zydus Pharmaceuticals (USA) won approval, announced October 20, for a once-weekly estradiol and levonorgestrel patch that treats moderate to severe hot flashes and prevents postmenopausal osteoporosis in women with an intact uterus. FDA says nine of 10 U.S. prescriptions are filled with generics but gave no price or savings figure for this product. So what: a first generic usually starts price competition, but the size of any discount is not public. Confidence: High on approval; Low on market impact. Sources: FDA press announcement.

Virginia: Negril Inc. and its owners will pay $1,817,910.60 to settle allegations they caused false claims to the Virginia Medicaid program. The Office of Inspector General (OIG) of HHS posted the October 19 settlement, announced by the U.S. Attorney’s Office for the Western District of Virginia, resolving claims under the federal False Claims Act and the Virginia Fraud Against Taxpayers Act. OIG’s page does not describe the billing conduct or period. So what: state and federal Medicaid dollars are being recovered under both laws at once. Confidence: High on amount and parties; Low on underlying conduct. Sources: HHS-OIG enforcement action.